Ponta Wealth Partners LLC Makes New Investment in AbbVie Inc. $ABBV

Ponta Wealth Partners LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,163 shares of the company’s stock, valued at approximately $723,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Chelsea Counsel Co. bought a new position in AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new stake in AbbVie in the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie during the 3rd quarter worth about $31,000. WestEnd Advisors LLC lifted its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. Finally, Caitlin John LLC bought a new position in shares of AbbVie in the 3rd quarter valued at about $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $252.90.

AbbVie Stock Down 0.5%

ABBV opened at $205.14 on Thursday. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81. The company has a fifty day simple moving average of $213.69 and a 200 day simple moving average of $221.19. The stock has a market cap of $362.72 billion, a P/E ratio of 101.05, a P/E/G ratio of 0.71 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the company posted $2.46 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 340.89%.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New long?term gastroenterology data — AbbVie presented 18 abstracts at Digestive Disease Week showing supportive long?term and real?world data for SKYRIZI (risankizumab) and RINVOQ (upadacitinib), which can bolster label positioning and commercial durability in IBD. AbbVie Highlights New Long-Term Data at DDW (PR Newswire)
• Positive Sentiment: Dividend appeal — several income-oriented outlets featured AbbVie as a high?yield, reliable dividend stock (Dividend King), which supports steady investor demand from income-focused funds. 6 Pharma Dividend Stocks Yielding Up to 6.44% (247WallSt)
• Positive Sentiment: Investor visibility — management will appear at the Bank of America Securities Healthcare Conference on May 13 (fireside chat), offering a chance for updated commercial color or guidance that could move the stock. AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
• Neutral Sentiment: Analyst/retail interest — multiple trending and “is it a buy?” pieces are driving attention but offer mixed views; useful for gauging retail flow rather than immediate fundamental change. Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
• Neutral Sentiment: Strategic/tech engagement — AbbVie appeared among industry leaders at Zifo’s SiEE summit on practical AI in life sciences; longer?term operational upside but unclear near?term impact. Zifo’s SiEE Boston Summit Charts New Roadmap (Yahoo)
• Neutral Sentiment: Peripheral industry moves — news such as Timothy P. Walbert joining Patient Square is industry?level and not directly tied to AbbVie fundamentals. Timothy P. Walbert Joins Patient Square Capital (Yahoo)
• Negative Sentiment: Regulatory/manufacturing setback — the U.S. FDA declined to approve AbbVie’s wrinkle treatment over manufacturing concerns (reported April 23), highlighting execution and regulatory risk that can weigh on aesthetics revenue and investor confidence. FDA Declines Approval of AbbVie Wrinkle Treatment (MSN)

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.